ASCERT subanalysis compares procedural costs over long term

11/12/2012 | TCTMD.com

At every point measured, bypass surgery was more expensive than percutaneous coronary intervention, even though CABG demonstrated cost-effectiveness over the longer term, according to a subanalysis of the ASCERT trial reported in the New England Journal of Medicine and discussed at the annual meeting of the American Heart Association. Session co-moderator Dr. Ralph Brindis said many concerns must be taken into account when treatment decisions are made: "As we [care for] the patient, we have to not only think about issues of quality, but accountability, transparency and cost."

View Full Article in:

TCTMD.com